In any Biotech company, there is always a promise of platform technology that enables it to produce many products. And investors and Biotech companies always consider which is the way to go – do they fund the developed of the Platform or the drug but it’s always a tossup between which is funded and which one is developed. There are no easy answers, but this has been analyzed and evaluated by many investors and they’re thinking as evident in one Blog that talks more about how that decision needs to be made and is made
Consider this:
https://a16z.com/platform-partnership-fit-for-bio-startups
And if you are biotech founder then use this blog post to consider this:
https://a16z.com/what-is-a-bio-platform-for
They ask the important questions such as what is the relative value of integration? Is there a compounding potential? What’s the bulls eye value for the platform? There are other questions such as what’s the breath of applicability? How critical is a technology? And, can the technology be demonstrated?
